This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
Willow Biosciences Launches Two Initiatives to Support CBG Offering
Company also promotes two executives.
Willow Biosciences Inc. has undertaken two initiatives to improve the understanding of cannabigerol (CBG), the company’s first commercial cannabinoid slated for production in the first quarter of 2021.
Willow has tapped Signum Biosciences, a biopharmaceutical company focused on the discovery and development of innovative consumer products, to generate a robust safety and data package for the company’s CBG to demonstrate its safety and activity as a cosmetic ingredient.